People · Operator
Named in public records as an officer, director or promoter · active 2021–2024 · Biotechnology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| i2O Therapeutics, Inc. | — | Biotechnology | Series B | $43.9M | $35.0M | 2022 |
| Otolith Sound, Inc. | — | Biotechnology | Series B | $30.9M | $33.8M | 2024 |
| Fount Bio, Inc. | — | Biotech / Pharma | Series A | $8.2M | $171.7M | 2021 |
| AdvanCell Isotopes Pty Ltd | — | Biotechnology | Series A | $5.0M | $34.5M | 2023 |
Anthony Aiudi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Anthony Aiudi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Samir Mitragotri | 2 | 4 |
| Kurt Graves | 1 | 5 |
| Dan Wagner | 1 | 4 |
| Katie Ellias | 1 | 3 |
| Kevin Cameron | 1 | 3 |
| Ravi Srinivasan | 1 | 3 |
| Justin Burns | 1 | 2 |
| Raphael Michel | 1 | 2 |
| Andrew Adamovich | 1 | 1 |
| William Ferris | 1 | 1 |
| Adrian Paterson | 1 | 1 |
| Simon Puttick | 1 | 1 |
| Michael Tung | 1 | 1 |
| Christopher Gagliardi | 1 | 1 |
| Mitragotri Mitragotri | 1 | 1 |
| Douglas Levinson | 1 | 1 |
| Tom Hardart | 1 | 1 |
| Samuel Owen | 1 | 1 |
| Kevin Franck | 1 | 1 |
| Jon Akers | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.